help me understand retatrutide, I have read the wiki twice
help me understand retatrutide, I have read the wiki twice. I am not trying to be the "source?" guy. I would just like a source.
Where the evidence actually stands, since every thread here assumes a different answer.
Phase 2 reported a large mean body weight change at 48 weeks across a few hundred participants with a slow, protocol-driven escalation. The effect size was striking. The confidence intervals were wide, the population was small, and the duration was under a year.
Phase 3 is running. Until it reports, everything else — including the ranking arguments this board loves — is extrapolation from a small study. That is not a criticism of the compound; it is a description of the evidence.
What the glucagon arm is doing, as best anyone can say from public data.
GLP-1 and GIP agonism cover appetite and insulin secretion in ways that are now reasonably well characterised. Glucagon receptor agonism is the third leg and it is associated with increased energy expenditure and with effects on hepatic fat.
Mechanistically that is why this compound reads as a different proposition rather than a stronger version of a dual agonist. Clinically, the size and durability of that difference in humans is precisely what is not yet established, and anyone telling you otherwise is filling a gap with confidence.
The standing caveat, written out properly because it keeps getting compressed into a footnote.
Nothing containing this compound is approved by any regulator. Research-use-only material is not approved for human use. That is not a legal formality on this board — it is why there is so little independent data, why the escalation schedules people post are invented, and why nobody here can answer a dosing question.
What this board can usefully do is read the published trials carefully, log independent purity results, and be honest about how thin the evidence base is. Everything else belongs somewhere with a clinician in it.
If two or three other people have done the same thing we might actually learn something. Alone it is an anecdote.
best — the order this archive was captured in
Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.
Left up. It reads the phase 2 paper carefully and it is honest about the intervals.
The nausea profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.
The nausea profile felt different rather than worse.
This is the sentence the rest of the board should read first. Phase 2 is not a label.
Agreed on the heart-rate reports. They are consistent enough across the threads to be worth noting, not enough to be a finding.
Right, and it bears repeating that nothing here is approved anywhere and research material is not for human use.
Cosigning the escalation point. Almost every difficult report on this board is from somebody who went up quickly.
That is body weight change, not fat mass. The trials report the first and people quote it as the second.
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.
Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.
Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.
The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation.
Agreed, and the glucagon arm is exactly why the comparison threads do not work.
Cosigning the escalation point.
Adding the standing caveat: none of this is approved anywhere and research material is not for human use.
Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.
The thing that surprised me was how much of the discussion here is inference rather than measurement.
the energy-expenditure story is mechanistically interesting and clinically unproven
a lot of the confident posting here is extrapolation
- 1Cosigning the escalation point. Almost every difficult report on this board…11 comments in this branch · started by u/andres_sorensen